- Home
- GSK vs SBUX Comparison
GSK vs SBUX Comparison
Compare GSK & SBUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GSK | SBUX |
|---|---|---|
| Founded | 1715 | 1971 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 96.1B | 105.7B |
| IPO Year | N/A | 1992 |
Fundamental Metrics
Financial Performance| Metric | GSK | SBUX |
|---|---|---|
| Price | $58.88 | $93.72 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 24 |
| Target Price | N/A | ★ $100.83 |
| AVG Volume (30 Days) | 6.9M | ★ 11.6M |
| Earning Date | 02-04-2026 | 01-28-2026 |
| Dividend Yield | ★ 2.84% | 2.64% |
| EPS Growth | ★ 123.15 | N/A |
| EPS | ★ 1.87 | 1.20 |
| Revenue | ★ $43,966,352,618.00 | $37,701,700,000.00 |
| Revenue This Year | $7.72 | $5.22 |
| Revenue Next Year | $4.59 | $5.53 |
| P/E Ratio | ★ $31.55 | $78.13 |
| Revenue Growth | 4.12 | ★ 4.30 |
| 52 Week Low | $32.38 | $75.50 |
| 52 Week High | $60.37 | $117.46 |
Technical Indicators
Market Signals| Indicator | GSK | SBUX |
|---|---|---|
| Relative Strength Index (RSI) | 74.38 | 49.45 |
| Support Level | $58.02 | $90.62 |
| Resistance Level | $60.37 | $101.20 |
| Average True Range (ATR) | 0.95 | 3.29 |
| MACD | 0.53 | -0.28 |
| Stochastic Oscillator | 86.64 | 22.32 |
Price Performance
Historical ComparisonAbout GSK GSK plc (Each representing two)
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
About SBUX Starbucks Corporation
Starbucks stands out as the world's biggest and most recognizable coffee brand, powered by ultracustomizable beverages in-store and a sweeping footprint of nearly 41,000 cafes in over 80 countries. About 52% are company-operated, with the balance run by licensees. The company operates roasteries and sells across its North America (74% of revenue as of the end of fiscal 2025), international (21%), and channel development (5%) segments. The brand collects revenue from company-operated stores, licensee royalties, equipment and product sales, retail ready-to-drink beverages, and packaged coffee.